CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 80 enrolled
Drug / intervention
Allopurinol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01228903
NCT01228903N/ACompleted
CompareCT.gov

Is Uric Acid a Mediator of Endothelial Dysfunction in Patients With Chronic Kidney Disease?

University of Colorado, Denver·interventional·Posted Oct 27, 2010·Updated Jun 28, 2017

In Brief

A clinical study evaluating Allopurinol and Placebo for Kidney Disease. Completed, enrolled 80 participants across 1 site.

Detailed Summary

This study will test the hypothesis that uric acid impairs the function of vessels in patients with kidney disease

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Disease
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 27, 2010
Enrollment StartOct 1, 2010
Primary CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 15.7 years ago

Interventions

Allopurinoldrug

Xanthine oxidase inhibitor- effective at lowering uric acid levels.

Placeboother

Placebo tablets with no active ingredient